Zurück zu Projekte

17517.2 PFLS-LS

17517.2 PFLS-LS

Zusammenfassung

Anti-cancer efficacy and mode of action dissection of a novel first-in class inhibitor of the Notch pathway

Weitere Texte

Abstract

Cellestia Biotech is developing first-in class oral small molecule inhibitor of the Notch pathway with a mechanism of action completely different from current therapies(GSIs and Mabs) in development to target this pathway. |The goal of this project is:|i) To dissect the mechanism of action of the novel inhibitor of Notch at molecular level.|ii) To explore the invivo anti-tumor efficacy, with a focus on Notch driven cancers that cannot be adressed by the current therapies.|

Beteiligte

Rajwinder Lehal

Wirtschaftspartner

raj.lehal@cellestia.com

Cellestia Biotech AG CHE-162.364.457 Rajwinder Lehal Hochbergerstr. 60C 4057 Basel BS CH

Freddy Radtke

Kontaktperson

freddy.radtke@epfl.ch

EPFL SV ISREC UPRAD Life Science Faculty Freddy Radtke Station 19 1015 Lausanne VD CH

Projektdetails

Forschungsstelle
INNOSUISSE
Projektstatus
Abgeschlossen
Projekttyp
Forschungsprojekt
Startdatum
2015-03-31
Enddatum
2016-09-30
Bewilligte Gesamtkosten
CHF 250056.00
Sektion
20 Förderbereich Life Sciences
NABS Politikbereich
Industrielle Produktivität und Technologie

Forschungsdisziplinen

  • T490 Biotechnology 100.0%